Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	30	26.77
Short-Term Investments	-	52.59
Cash & Short-Term Investments	30	79.36
Cash Growth	-62.19%	-
Receivables	12.75	7.32
Inventory	38.48	14.41
Prepaid Expenses	13.47	5.61
Total Current Assets	94.71	106.7
Property, Plant & Equipment	36.63	35.1
Other Intangible Assets	1.99	2.04
Other Long-Term Assets	6.67	5.67
Total Assets	139.99	149.51
Accounts Payable	5.87	6.19
Accrued Expenses	13.69	7.36
Current Portion of Leases	2.1	1.91
Current Unearned Revenue	0.47	0.58
Other Current Liabilities	1.6	0.56
Total Current Liabilities	23.73	16.59
Long-Term Debt	9.81	-
Long-Term Leases	29.56	31.19
Other Long-Term Liabilities	0.85	0.15
Total Liabilities	63.95	47.93
Common Stock	0	0
Additional Paid-In Capital	9.89	5.39
Retained Earnings	-168.78	-138.96
Comprehensive Income & Other	-0.07	0.15
Total Common Equity	-158.95	-133.41
Shareholders' Equity	76.04	101.59
Total Liabilities & Equity	139.99	149.51
Total Debt	41.47	33.1
Net Cash (Debt)	-11.47	46.26
Net Cash Per Share	-0.41	1.61
Filing Date Shares Outstanding	29.13	26.82
Total Common Shares Outstanding	29.13	26.82
Working Capital	70.98	90.11
Book Value Per Share	-5.46	-4.97
Tangible Book Value	-160.94	-135.46
Tangible Book Value Per Share	-5.52	-5.05
Machinery	17.73	12.88
Leasehold Improvements	1.05	0.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q